Literature DB >> 30880064

Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes.

Woo Jin Lee1, Ye Jin Lee2, Myoung Eun Choi2, Kyung A Yun2, Chong Hyun Won2, Mi Woo Lee2, Jee Ho Choi2, Sung Eun Chang3.   

Abstract

BACKGROUND: Lymphocyte-activating gene 3 (LAG-3) and T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif (TIGIT) domains are emerging checkpoint proteins.
OBJECTIVE: We evaluated LAG-3 and TIGIT protein expression patterns, correlated these patterns with programmed cell death 1 (PD-1) protein expression, and determined their effects on clinicopathologic characteristics and biologic responses in melanoma.
METHODS: Diagnostic tissue from 124 patients with melanoma were evaluated for LAG-3, TIGIT, and PD-1 expression by immunohistochemistry. Clinicopathologic features and survival were analyzed according to the expression of LAG-3, TIGIT, and PD-1.
RESULTS: LAG-3 and TIGIT expression on tumor-infiltrating lymphocytes were significantly correlated with that of PD-1 and was also significantly associated with negative prognostic factors: deeper Breslow thickness, lymph node involvement, and advanced stage of disease. However, PD-1 expression was not associated with clinicopathologic variables of prognostic significance. High expression of either LAG-3 or TIGIT was associated with worse survival. Subgroup analysis on the basis of Breslow thickness showed that both LAG-3 and TIGIT have prognostic significance regardless of tumor thickness. High expression of PD-1 was not predictive of survival. LIMITATIONS: Retrospective study in a single institution and possibility of type 1 error.
CONCLUSION: Expression of LAG-3 and TIGIT represents an independent unfavorable prognostic factor in cutaneous melanoma.
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  LAG-3; PD-1; TIGIT; melanoma; survival; tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2019        PMID: 30880064     DOI: 10.1016/j.jaad.2019.03.012

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  17 in total

1.  TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism.

Authors:  Kaikai Zhao; Liyang Jiang; Youjiao Si; Shujie Zhou; Zhaoqin Huang; Xiangjiao Meng
Journal:  Cancer Immunol Immunother       Date:  2022-07-06       Impact factor: 6.968

Review 2.  TIGIT as an emerging immune checkpoint.

Authors:  H Harjunpää; C Guillerey
Journal:  Clin Exp Immunol       Date:  2019-12-25       Impact factor: 4.330

3.  Clinical significance of LSECtin and its association with PVR in non-small-cell lung cancer patients.

Authors:  Yizhong Zhang; Huanling Lai; Peipei Chen; Dan Li; Imran Khan; Wen Luan Wendy Hsiao; Xingxing Fan; Xiaojun Yao; Qibiao Wu; Meifang Wang; Elaine Laihan Leung
Journal:  Ann Transl Med       Date:  2020-11

4.  [The expression and prognostic value of PD-1, TIM-3, LAG-3 and BTLA in extranodal NK/T cell lymphoma].

Authors:  L Nie; X Y Liu; R J Ma; X L Yuan; L Jiang; J Yang; A X Hu; Z Li; Z M Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-07-14

Review 5.  Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.

Authors:  Vera Petrova; Ihor Arkhypov; Rebekka Weber; Christopher Groth; Peter Altevogt; Jochen Utikal; Viktor Umansky
Journal:  Int J Mol Sci       Date:  2020-03-30       Impact factor: 5.923

Review 6.  Alternative Checkpoints as Targets for Immunotherapy.

Authors:  Ayush Pant; Ravi Medikonda; Michael Lim
Journal:  Curr Oncol Rep       Date:  2020-11-03       Impact factor: 5.075

7.  Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis.

Authors:  Mengzhou Guo; Feifei Yuan; Feng Qi; Jialei Sun; Qianwen Rao; Zhiying Zhao; Peixin Huang; Tingting Fang; Biwei Yang; Jinglin Xia
Journal:  J Transl Med       Date:  2020-08-06       Impact factor: 5.531

Review 8.  Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment.

Authors:  Qin Xie; Jian Ding; Yi Chen
Journal:  Acta Pharm Sin B       Date:  2021-04-24       Impact factor: 11.413

Review 9.  Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.

Authors:  Katrin Pansy; Barbara Uhl; Jelena Krstic; Marta Szmyra; Karoline Fechter; Ana Santiso; Lea Thüminger; Hildegard Greinix; Julia Kargl; Katharina Prochazka; Julia Feichtinger; Alexander Ja Deutsch
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

10.  Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.

Authors:  Mengzhou Guo; Feng Qi; Qianwen Rao; Jialei Sun; Xiaojing Du; Zhuoran Qi; Biwei Yang; Jinglin Xia
Journal:  Front Immunol       Date:  2021-10-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.